Supporting Information

Au-Allenylidene Promoted Decarboxylative Intramolecular α -Attacking Annulation to Access Unsaturated γ -Lactams/Lactones

Xuelun Duan, Haotian Shi, Yangyang Yue, Wangze Song*

Central Hospital of Dalian University of Technology, School of Chemistry, School of Chemical Engineering Dalian University of Technology, Dalian, 116024, P. R. China

wzsong@dlut.edu.cn

1.	General remarks	2
2.	General procedure for the preparation of substrates	2
3.	Representative procedures for the synthesis of cyclic ethynylethylene carbamates	2
4.	Representative procedures for the synthesis of cyclic ethynylethylene carbonates	3
5.	Representative procedures for the synthesis unsaturated γ-lactams/lactones	4
6.	The procedure for the synthesis of <i>N</i> -H unsaturated γ -lactam 6 from 30	5
7.	The procedure for the synthesis of <i>N</i> -H unsaturated γ -lactam 6 from 3ac	5
8.	The procedure for the synthesis of rubrolide derivative	6
9.	Other optimization reaction conditions	6
10.	The applications of this method	7
11.	Mechanistic experiments	9
12.	Characterization data of products	11
13.	References	25
14.	NMR spectra	26

1. General remarks

Unless otherwise noted, all commercially available reagents and solvents were used without further additional purification. Thin layer chromatography was performed using precoated silica gel plates and visualized with UV light at 254 nm. Flash column chromatography was performed with silica gel (40-60µm). ¹H and ¹³C nuclear magnetic resonance spectra (NMR) were obtained on Bruker Avance II 400 MHz, Bruker Avance III 500 MHz and Bruker Avance NEO 600M recorded in ppm (δ) downfield of TMS (δ =0) in CDCl₃ unless noted otherwise. Signal splitting patterns were described as singlet (s), doublet (d), triplet(t), quartet (q), quintet (quint), or multiplet (m), with coupling constants (*J*) in hertz (Hz). High resolution mass spectra (HRMS) were performed by an Agilent apparatus (TOF mass analyzer type) on an Electron Spray Injection (ESI) mass spectrometer. Melting points were determined by an XP-4 melting point apparatus.

2. General procedure for the preparation of substrates

Compounds 2 are commercially available.

The cyclic ethynylethylene carbamates **1** were prepared according to the literature.^{S1} The cyclic ethynylethylene carbonates **3** were prepared according to the literatures.^{S2-S3}

3. Representative procedures for the synthesis of cyclic

ethynylethylene carbamates

A typical procedure is described as following for the synthesis of 1a:

 Trimethylsilylacetylene (3.43 g, 35.0 mmol, 3.5 equiv) was dissolved into 50 mL THF and cooled to 0°C, then ⁿBuLi (30.0 mmol, 2.5 M in Hexane, 12 mL, 3.0 equiv) was added and stirred at this temperature for 1 h under argon atmosphere. The mixture was then cooled to -78 °C, and I (2.35 g, 10.0 mmol, 1.0 equiv) in 10 mL THF was added. The mixture was allowed to stir at this temperature for further 10 min before being warmed to room temperature and stirred overnight. A saturated solution of NH₄Cl (20 mL) was added and the aqueous phase was extracted with EtOAc (3×20 mL). The combined extracts were dried by Na₂SO₄ and concentrated under reduced pressure. The crude product was used next step directly without further purification. The crude product was dissolved in THF (30 mL) and cooled to -78 °C. TBAF (10 mmol, 1.0 M in THF, 10 mL, 1.0 equiv) was added and stirred for 1 h at this temperature before being quenched with a saturated solution of NH₄Cl (10 mL). The mixture was extracted with EtOAc (3×20 mL), and the organic mixture was dried by Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc = 1:1) to give the product **II** (1.40 g, 75% yield) as a brown solid.

2) II (374 mg, 2.0 mmol, 1.0 equiv) and Et₃N (405 mg, 4.0 mmol, 2.0 equiv) were dissolved in DCM (5 mL). The mixture was then cooled to 0°C, and TsCl (570 mg, 3.0 mmol, 1.5 equiv) was added dropwise. The mixture was warmed to room temperature and stirred for 8 h before quenched with saturated solution of NH₄Cl (5 mL). The mixture was extracted with DCM (3×10 mL). The organic mixture was dried by Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc = 2:1) to give the cyclic ethynylethylene carbamates 1a (545 mg, 80% yield) as a brown solid.

4. Representative procedures for the synthesis of cyclic

ethynylethylene carbonates



A typical procedure is described as following for the synthesis of 4a:

- To the solution of I (272 mg, 2.0 mmol, 1.0 equiv) in THF (5 mL) was dropped ethynylmagnesium bromide (6.0 mmol, 0.5 M in THF, 12 mL, 3.0 equiv) at 0 °C. The mixture was then stirred for 12 h at room temperature. After quenched with saturated solution of NH₄Cl (10 mL). The mixture was extracted with EtOAc (3x20 mL). The organic mixture was dried by Na₂SO₄ and concentrated under reduced pressure to give the crude product **II**.
- 2) The crude product II and pyridine (632 mg, 8.0 mmol, 4.0 equiv) were dissolved into 8 mL DCM and cooled to 0 °C, then triphosgene (293 mg, 1.0 mmol in 1 mL DCM, 0.5 equiv) was added. The mixture was stirred at room temperature for 6 h, and then concentrated under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc = 2:1) to afford the cyclic ethynylethylene

carbonate 4a (263 mg, 70% yield) as yellow oil.

5. Representative procedures for the synthesis unsaturated γ -

lactams/lactones



A typical procedure is described as following for the synthesis of **3a**: AuCl₃ (2.3 mg, 7.5 mol%) and **L5** (10.0 mg, 15 mol%) were added to a vial containing MeCN (1 mL) to stir 10 min under N₂ atmosphere. Cyclic ethynylethylene carbonate **4a** (34.1 mg, 0.10 mmol, 1.0 equiv), 4-(methoxy)pyridine-*N*-oxide **2c** (18.8 mg, 0.15 mmol, 1.5 equiv) and Et₃N (47.0 mg, 0.2 mmol, 2.0 equiv) were added into the solution. The mixture was stirred for 6 h at 70 °C (heating mantle). The solvent was removed under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc = 3:1) to afford the unsaturated γ -lactam **3a** (38 mg, 78% yield) as brown solid.



A typical procedure is described as following for the synthesis of **5a**: AuCl₃ (4.6 mg, 7.5 mol%) and **L5** (20.0 mg, 15 mol%) were added to a vial containing MeCN (2 mL) to stir 10 min under N₂ atmosphere. Cyclic ethynylethylene carbamate **1a** (34.1 mg, 0.20 mmol, 1.0 equiv), 4-(methoxy)pyridine-*N*-oxide **2c** (37.6 mg, 0.30 mmol, 1.5 equiv) and Et₃N (94.0 mg, 0.40 mmol, 2.0 equiv) were added into the solution. The mixture was stirred for 6 h at 70 °C (heating mantle). The solvent was removed under reduced pressure. The residue was then purified by flash column chromatography (PE/EtOAc = 3:1) to afford the unsaturated γ -lactone **5a** (22.4 mg, 70% yield) as brown solid.

6. The procedure for the synthesis of N-H unsaturated γ -lactam 6

from 3o



The solution of **3o** (34.7 mg, 0.10 mmol, 1.0 equiv) in dry benzene (3 mL) was heated to reflux, Bu₃SnH (64 mg, 0.22 mmol, 2.2 equiv) and AIBN (3.5 mg, 20 mol%) in dry benzene (3 mL) were added as a solution. The reaction was stirred at 95 °C until TLC analysis showed that **3o** was completely consumed. Then the solvent was removed under reduced pressure. Diethyl ether (5 mL), saturated KF (1.5 mL), and water (5 mL) were added, and the resulting mixture was stirred overnight. The water layer was extracted with DCM. The combined organic layer was dried by Na₂SO₄, and concentrated under reduced pressure. The residue then purified by flash column chromatography (PE/EtOAc = 2:1) to give product **6** (16.4 mg, 85% yield) as brown solid.

7. The procedure for the synthesis of N-H unsaturated γ -lactam 6

from 3ac



Unsaturated γ -lactam **3ac** (29.3 mg, 0.1 mmol, 1.0 equiv) was added to a vial containing DCM (2 mL). Then TFA (66 μ L, 0.4 mmol, 4.0 equiv) was added. The vial was closed and the mixture was stirred for 1 h at room temperature. After removing the solvent under reduced pressure, the residue was purified with flash column chromatography (PE/EtOAc = 2:1) to give the product **6** (18.7 mg, 97% yield) as brown solid.

8. The procedure for the synthesis of rubrolide derivative



Unsaturated γ -lactone **5a** (16.0 mg, 0.1 mmol, 1.0 equiv), benzaldehyde (12.7 mg, 0.12 mmol, 1.2 equiv), and ethylenediamine (1.2 mg, 20 mol%) were added to a vial containing MeOH (0.2 mL). the solution was heated to reflux and stirred for 6 h. The solvent was removed under reduced pressure, the residue was purified with flash column chromatography (PE/EtOAc = 8:1) to give the product **9** (18.7 mg, 97% yield) as brown solid.

9. Other optimization reaction conditions

Other reaction conditions were subsequently investigated in Table S1. When DMSO and DMF were used as solvents instead of MeCN, only a trace product was observed (Table S1, entries 2-3). To our delight, this reaction could tolerate various small and moderately polar solvents to facilitate the annulation reaction (Table S1, entries 4-7). Surprisingly, protonic solvent MeOH could also be used as a solvent for such transformation to provide **3a** (Table S1, entry 8), indicating that the intramolecular α attacking process is very rapid. Overall, MeCN was chosen as the most suitable solvent to afford **3a**. If the reaction temperature was dropped to room temperature, no reaction occurred. (Table S1, entry 9). At relatively low temperatures of 60 °C, the reaction slowed down(Table S1, entry 10). In addition, no obvious improvement of yield for **3a** was observed for the transformation when the reaction temperature was increased to 90 °C, (Table S1, entry 11). Neither increasing nor decreasing the reaction time could further increase the yield(Table S1, entries 12-13).

Table S1.	Other o	ptimization	reaction	conditions ^{<i>a,b</i>}

	O AuCl ₃ , O Ph Solve	L5 t_3N Ts $-N$ Ph ont O 3a	
Entry	Solvent	Temp.(°C)	Yield[%]
1	MeCN	70	78
2	DMSO	70	trace
3	DMF	70	trace
4	toluene	70	45
5	1,4-dioxane	70	48
6	DCE	70	52
7	acetone	70	64
8	EtOH	70	50
9	MeCN	r.t.	n.r.
10	MeCN	60	40
11	MeCN	90	70
12 ^c	MeCN	70	48
13 ^d	MeCN	70	78

^aConditions: **1a** (1.0 equiv), **2c** (1.5 equiv), Et₃N (2.0 equiv), AuCl₃ (7.5 mol%), **L5** (15 mol%), solvent (0.1 M), 70 °C for 4 h. ^bIsolated yield of **3a**. ^c2h. ^d8h

10.The applications of this method

Many y-lactams and y-lactones own excellent bioactivities, which are applied in medicinal chemistry and biological science. Subsequently, the applicability for the synthesis of drugs and natural product analogues from unsaturated y-lactams/lactones was conducted in Scheme S1. It was very easy to deprotection **30** or **3ac** by releasing Ts- or Boc- protecting group to form N-H unsaturated γ -lactam 6 in 85% and 97% yield, respectively (Scheme S1A). Unsaturated γ -lactam 6 could be efficiently transformed into the gamma-aminobutyric acid (GABA)-b receptor agonist (R)-Baclofen hydrochloride 7 according to literature reported.^{S4} In addition, compound 6 could also be utilized as a precursor to synthesize antimalarial analogues 8.⁸⁵ Besides unsaturated y-lactams 3, unsaturated y-lactones 5 could also be converted to diverse

bioactive natural products (Scheme S1B). A highly efficient synthesis of Rubrolide derivative **9** in 91% yield within one step was achieved using unsaturated γ -lactones **5a** as substrate. The highly unsaturated γ -lactones **9** exhibited powerful antibacterial and anti-tumor activities.^{S6-S7} Furthermore, the Arctigenin analogue **10** could be prepared from unsaturated γ -lactone **5b** by a two-step reaction.^{S8} (Scheme S1).

A) Conversion of Unsaturated γ-Lactams



Scheme S1. Conversion of unsaturated γ -lactams/lactones into drugs and natural Products

11.Mechanistic experiments

As shown in Scheme S2, cyclic ethynylethylene carbonate **1a** was used as substrate to achieve this transformation. In the absence of 4-(methoxy)pyridine-*N*-oxide **2c** or using H_2O_2 instead of **2c**, no desired product **3a** was observed.



Scheme S2. Control experiments

When benzyl alcohol was added as an additional nucleophilic reagent in the reaction, no α,β -unsaturated ester was observed, indicating that intramolecular nucleophilic attack is a very rapid process.



Scheme S3. Orthogonal reaction

4-Methoxypyridine **D'** obtained from the reduction of **2c** was trapped by HRMS in situ. (EI, m/z 110.0601) (calcd for (M+H)⁺ [C₆H₈NO] is 110.0600).



Proposed Mechanism:

A possible mechanism for Au-allenvlidene promoted decarboxylative annulation was proposed in Scheme S4. The reaction initially starts by the formation of a gold π complex with terminal alkyne A, which is deprotonated with base to afford a gold σ complex (gold acetylide complex) **B**. Subsequent decarboxylative ring opening of **B** gives the cationic intermediate C, which further generates Au-allenylidene C' as a resonance structure. At the same time, the nucleophilic moiety is released within the same molecular structure. Subsequently, the Au-allenylidene complex C' is oxidized in an anti-Markovnikov oxidation manner by pyridine N-oxide D to form alkylidene ketene E. The pyridine D' is obtained from the reduction of pyridine N-oxide D, which is confirmed by HRMS (ESI, m/z 110.0601) (calcd for $(M+H)^+$ [C₆H₈NO] is 110.0600) (Fig. S1). Significantly, due to the presence of sulforyl or acyl groups, the nucleophilicity of nitrogen is greatly reduced, which severely blocks the intermolecular α -nucleophilic attack to allenylidene which usually results in the formation of allenes. In addition, the oxidation of Au-allenylidene C' to alkylidene ketene E is much faster than intramolecular α -nucleophilic attack to allenvlidene. That's why only trace amount of pyrrole \mathbf{F} as by-product is observed. Subsequently, alkylidene ketene E is rapidly trapped by the nucleophilic moiety by 5-endo-dig intramolecular annulation to obtain unsaturated γ -lactams/lactones products 3.



Scheme S4. Proposed reaction mechanism.

12. Characterization data of products

$$Ts - N$$
 Ph

4-Phenyl-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3a)

23.5 mg, 78% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl3) δ 8.02 (d, *J* = 8.1 Hz, 2H), 7.60 – 7.43 (m, 5H), 7.36 (d, *J* = 8.0 Hz, 2H), 6.33 (s, 1H), 4.86 (s, 2H), 2.45 (s, 3H).

Compound 3a is known compound, and the proton spectrum is fully consistent with literature reported.^{S9}



4-Phenyl-1-(phenylsulfonyl)-1,5-dihydro-2*H*-pyrrol-2-one (3b)

23.3 mg, 78% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 135-137°C. ¹H NMR (400 MHz, CDCl₃) δ 8.18 – 8.11 (m, 2H), 7.71 – 7.63 (m, 1H), 7.59 (d, *J* = 7.6 Hz, 2H), 7.54 – 7.43 (m, 5H), 6.35 (s, 1H), 4.88 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 168.5, 157.8, 138.5, 134.0, 131.7, 130.5, 129.3, 129.2, 128.0, 126.2, 118.6, 51.8. HRMS (ESI-TOF) m/z calcd for C₁₆H₁₃NO₃S (M+H)⁺ 300.0689, found 300.0694.



1-((4-Methoxyphenyl)sulfonyl)-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3c)

47 mg, 84% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 146-148°C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 9.0 Hz, 2H), 7.54 – 7.42 (m, 5H), 7.00 (d, *J* = 9.0 Hz, 2H), 6.31 (t, *J* = 1.6 Hz, 1H), 4.84 (d, *J* = 1.6 Hz, 2H), 3.87 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.6, 164.0, 157.7, 131.6, 130.5, 130.3, 129.9, 129.3, 126.2, 118.7, 114.4, 55.7, 51.8. HRMS (ESI-TOF) m/z calcd for C₇H₁₅NO₄S (M+H)⁺ 330.0795, found 330.0793.



1-((4-(Tert-butyl)phenyl)sulfonyl)-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3d)

24.1 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 148-150°C. ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 8.6 Hz, 2H), 7.56 (d, *J* = 1.7 Hz, 2H), 7.52 – 7.42 (m, 5H), 6.35 (t, *J* = 1.6 Hz, 1H), 4.85 (d, *J* = 1.6 Hz, 2H), 1.33 (s, 9H). ¹³C NMR (150 MHz, CDCl₃) δ 168.6, 158.0, 157.7, 135.4, 131.7, 130.5, 129.3, 127.8, 126.3, 126.2, 118.8, 51.8, 35.3, 31.0. HRMS (ESI-TOF) m/z calcd for C₂₀H₂₁NO₃S (M+H)⁺356.1315, found 356.1316.



1-((4-Chlorophenyl)sulfonyl)-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3e)

23.3 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 138-140°C. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.4 Hz, 2H), 7.62 – 7.45 (m, 7H), 6.35 (s, 1H), 4.87 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 168.5, 158.1, 140.8,

136.8, 131.8, 130.4, 129.5, 129.5, 129.4, 126.2, 118.5, 51.7. HRMS (ESI-TOF) m/z calcd for $C_{16}H_{12}CINO_3S$ (M+H)⁺ 334.0299, found 334.0300.



1-((4-Nitrophenyl)sulfonyl)-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3f)

22.4 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (600 MHz, CDCl₃) δ 8.42 – 8.28 (m, 4H), 7.57 – 7.40 (m, 5H), 6.34 (s, 1H), 4.89 (s, 2H).

Compound **3f** is known compound, and the proton spectrum is fully consistent with literature reported.^{S10}

1-(Methylsulfonyl)-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3g)

18.0 mg, 76% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 130-132°C. ¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.45 (m, 5H), 6.46 (s, 1H), 4.86 (s, 2H), 3.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 158.5, 131.8, 130.4, 129.4, 126.3, 118.4, 51.1, 41.1. HRMS (ESI-TOF) m/z calcd for C₁₁H₁₁NO₃S (M+H)⁺ 238.0532, found 238.0533.

1-Benzoyl-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3h)

16.0 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 134-136°C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 – 7.63 (m, 4H), 7.58 – 7.42 (m, 6H), 6.46 (s, 1H), 5.04 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 168.9, 156.8, 135.4, 131.5, 130.7, 129.3, 128.7, 128.6, 128.5, 128.4, 126.3, 119.4, 51.0. HRMS (ESI-TOF) m/z calcd for C₁₇H₁₃NO₂ (M+H)⁺ 264.1019, found 264.1020.



1-(Furan-2-carbonyl)-4-phenyl-1,5-dihydro-2H-pyrrol-2-one (3i)

16.4 mg, 65% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 128-130°C. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 3.7 Hz, 1H), 7.66 (d, *J* = 1.7 Hz, 1H), 7.65 – 7.60 (m, 2H), 7.52 – 7.48 (m, 3H), 6.59 – 6.57 (m, 1H), 6.46 (s, 1H),

5.00 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 168.7, 157.8, 157.4, 146.7, 146.3, 131.6, 130.7, 129.3, 126.4, 120.8, 119.0, 111.9, 51.1. HRMS (ESI-TOF) m/z calcd for C₁₅H₁₁NO₃ (M+H)⁺ 254.0812, found 254.0816.

4-Phenyl-1-(2-phenylacetyl)-1,5-dihydro-2*H*-pyrrol-2-one (3j)

18.6 mg, 67% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 133-135°C. ¹H NMR (600 MHz, CDCl₃) δ 7.60 – 7.56 (m, 2H), 7.49 – 7.46 (m, 3H), 7.39 – 7.31 (m, 5H), 6.44 (t, *J* = 1.6 Hz, 1H), 4.79 (d, *J* = 1.5 Hz, 2H), 4.38 (s, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 171.0, 169.9, 157.8, 134.2, 131.6, 130.7, 129.8, 129.3, 128.5, 127.0, 126.4, 119.2, 50.4, 42.5. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₅NO₂ (M+H)⁺ 278.1176, found 278.1180.

1-Acetyl-4-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (3k)

12.5 mg, 62% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 6.7 Hz, 2H), 7.50 (d, *J* = 6.6 Hz, 3H), 6.47 (s, 1H), 4.80 (s, 2H), 2.63 (s, 3H).

Compound 3k is known compound, and the proton spectrum is fully consistent with literature reported.^{S11}

Tert-butyl 2-oxo-4-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxylate (3l)

17.1 mg, 66% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.57 (dd, J = 6.1, 3.0 Hz, 2H), 7.48 (d, J = 5.5 Hz, 3H), 6.44 (s, 1H), 4.72 (s, 2H), 1.62 (s, 9H).

Compound **3l** is known compound, and the proton spectrum is fully consistent with literature reported.^{S12}



4-(4-Methoxyphenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3m)

24.7 mg, 72% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 142-144°C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 – 7.97 (m, 2H), 7.50 – 7.44 (m, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.00 – 6.94 (m, 2H), 6.19 (s, 1H), 4.82 (s, 2H), 3.88 (s, 3H), 2.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.9, 162.4, 157.4, 145.0, 135.7, 129.8, 128.0, 127.9, 123.1, 116.3, 114.7, 55.5, 51.7, 21.6. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₄S (M+H)⁺ 344.0951, found 344.0953.



4-(*p*-Tolyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3n)

23.5 mg, 72% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 148-150°C. ¹H NMR (400 MHz, CDCl₃) δ 7.96 – 7.83 (m, 2H), 7.35 – 7.29 (m, 2H), 7.26 (d, *J* = 8.1 Hz, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 6.17 (d, *J* = 1.5 Hz, 1H), 4.73 (d, *J* = 1.5 Hz, 2H), 2.35 (s, 3H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.8, 157.8, 145.1, 142.4, 135.6, 130.0, 129.8, 128.0, 127.8, 126.2, 117. 51.8, 21.7, 21.6. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₃S (M+H)⁺ 328.1002, found 328.1006.



4-(4-Chlorophenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (30)

24.3 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 140-142°C. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.0 Hz, 2H), 7.45 (d, *J* = 1.2 Hz, 4H), 7.37 (d, *J* = 8.0 Hz, 2H), 6.32 (s, 1H), 4.83 (s, 2H), 2.45 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.3, 156.3, 145.3, 137.8, 135.4, 129.9, 129.7, 129.0, 128.0, 127.4, 119.2, 51.6, 21.7. HRMS (ESI-TOF) m/z calcd for C₁₇H₁₄ClNO₃S (M+H)⁺ 348.0456, found 348.0460.



4-(4-Bromophenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3p)

26.9 mg, 69% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 138-140°C. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 8.3 Hz, 2H), 7.59 (d, *J* = 8.6 Hz, 2H), 7.39 – 7.33 (m, 4H), 6.31 (t, *J* = 1.6 Hz, 1H), 4.80 (d, *J* = 1.5 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.2, 156.3, 145.3, 135.4, 132.6, 129.8, 129.4, 128.0, 127.6, 126.2, 119.3, 51.6, 21.7. HRMS (ESI-TOF) m/z calcd for C₁₇H₁₄BrNO₃S (M+H)⁺ 391.9951, found 391.9952.



4-(*m*-Tolyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3q)

23.9 mg, 73% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 137-139°C. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.4 Hz, 2H), 7.41 – 7.30 (m, 6H), 6.31 – 6.30 (m, 1H), 4.84 (d, *J* = 1.5 Hz, 2H), 2.45 (s, 3H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.6, 158.0, 145.1, 139.1, 135.6, 132.5, 130.5, 129.8, 129.2, 128.0, 126.8, 123.4, 118.5, 51.8, 21.7, 21.4. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₃S (M+H)⁺ 328.1002, found 328.1005.



4-(3-Methoxyphenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3r)

24.4 mg, 71% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 141-143°C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 – 7.98 (m, 2H), 7.42 – 7.32 (m, 3H), 7.13 – 7.00 (m, 3H), 6.31 (s, 1H), 4.83 (s, 2H), 3.86 (s, 3H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.5, 160.2, 157.7, 145.2, 135.5, 131.8, 130.4, 129.8, 128.0, 119.0, 118.6, 117.0, 111.8, 55.5, 51.8, 21.7. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₄S (M+H)⁺ 344.0951, found 344.0955.



4-(3-Chlorophenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3s)

23.6 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 140-142°C. ¹H NMR (600 MHz, CDCl₃) δ 7.92 (d, *J* = 8.4 Hz, 2H), 7.40 (q, *J* = 1.4 Hz, 1H), 7.31 (d, *J* = 1.2 Hz, 1H), 7.28 (d, *J* = 8.1 Hz, 2H), 7.19 (s, 2H), 6.26 – 6.25 (m, 1H), 4.74 (d, *J* = 1.5 Hz, 2H), 2.36 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.0, 156.1, 145.3, 135.5, 135.4, 132.3, 131.5, 130.6, 129.9, 128.1, 126.3, 124.3, 120.1,

51.6, 21.7. HRMS (ESI-TOF) m/z calcd for $C_{17}H_{14}CINO_3S (M+H)^+ 348.0456$, found 348.0459.



4-(3-Bromophenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3t)

27.3 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 143-145°C. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.1 Hz, 2H), 7.66 – 7.60 (m, 2H), 7.45 (d, *J* = 7.8 Hz, 1H), 7.39 – 7.35 (m, 3H), 6.34 (s, 1H), 4.82 (s, 2H), 2.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 156.0, 145.3, 135.4, 134.4, 132.5, 130.8, 129.9, 129.2, 128.0, 124.7, 123.5, 120.1, 51.6, 21.7. HRMS (ESI-TOF) m/z calcd for C₁₇H₁₄BrNO₃S (M+H)⁺ 391.9951, found 391.9953.



4-(o-Tolyl)-1-tosyl-1,5-dihydro-2H-pyrrol-2-one (3u)

20.6 mg, 63% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 146-148°C. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 8.3 Hz, 2H), 7.39 – 7.28 (m, 6H), 6.28 (t, *J* = 1.6 Hz, 1H), 4.82 (d, *J* = 1.5 Hz, 2H), 2.43 (s, 3H), 2.39 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.7, 158.0, 145.1, 139.1, 135.5, 132.5, 130.4, 129.8, 129.2, 128.0, 126.8, 123.4, 118.5, 51.8, 21.7, 21.4. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₃S (M+H)⁺ 328.1002, found 328.1007.



4-(2-Methoxyphenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3v)

20.9 mg, 61% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 148-150°C. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.3 Hz, 2H), 7.49 – 7.30 (m, 4H), 7.10 – 6.95 (m, 2H), 6.56 (t, *J* = 1.5 Hz, 1H), 4.89 (d, *J* = 1.5 Hz, 2H), 3.92 (s, 3H), 2.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 158.6, 154.8, 144.9, 135.7, 132.7, 129.8, 128.3, 128.0, 126.5, 121.4, 121.0, 111.7, 55.5, 53.4, 21.6. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₄S (M+H)⁺ 344.0951, found 344.0957.



4-(2-Fluorophenyl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3w)

17.9 mg, 54% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 139-141°C. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 8.1 Hz, 2H), 7.51 – 7.44 (m, 2H), 7.37 (d, J = 8.1 Hz, 2H), 7.27 – 7.15 (m, 2H), 6.49 (s, 1H), 4.89 (s, 2H), 2.45 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.4, 162.0, 160.3, 152.1, 145.2, 135.5, 133.1 (d, J = 9.6 Hz), 129.8, 128.0, 124.9 (d, J = 3.4 Hz), 122.5 (d, J = 9.7 Hz), 118.8 (d, J = 12.0 Hz), 117.0 (d, J = 21.9 Hz), 52.7 (d, J = 5.8 Hz), 21.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -109.4. HRMS (ESI-TOF) m/z calcd for C₁₇H₁₄FNO₃S (M+H)⁺ 332.0751, found 332.0757.



4-([1,1'-Biphenyl]-4-yl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3x)

29.6 mg, 76% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid, mp = 151-153°C. ¹H NMR (600 MHz, CDCl₃) δ 8.01 (d, *J* = 8.4 Hz, 2H), 7.67 (d, *J* = 8.3 Hz, 2H), 7.62 – 7.60 (m, 2H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.41 – 7.39 (m, 1H), 7.35 (d, *J* = 8.2 Hz, 2H), 6.34 – 6.33 (m, 1H), 4.87 (d, *J* = 1.5 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.6, 157.3, 145.2, 144.4, 139.6, 135.5, 129.8, 129.3, 129.1, 128.3, 128.0, 127.9, 127.1, 126.7, 118.5, 51.8, 21.7. HRMS (ESI-TOF) m/z calcd for C₂₃H₁₉NO₃S (M+H)⁺ 390.1158, found 390.1162.



4-(Naphthalen-2-yl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3y)

24.7 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid, mp = 148-150°C. ¹H NMR (600 MHz, CDCl₃) δ 8.02 (d, *J* = 8.4 Hz, 2H), 7.93 (d, *J* = 1.8 Hz, 1H), 7.90 – 7.84 (m, 3H), 7.60 – 7.55 (m, 3H), 7.35 (d, *J* = 8.2 Hz, 2H), 6.42 – 6.41 (m, 1H), 4.97 (d, *J* = 1.5 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.6, 157.6, 145.2, 135.6, 134.6, 133.0, 129.8, 129.2, 128.8, 128.1, 128.0, 127.9, 127.8, 127.3, 126.3, 123.0, 119.0, 51.8, 21.7. HRMS (ESI-TOF) m/z calcd for C₂₁H₁₇NO₃S (M+H)⁺ 364.1002, found 364.1009.



4-(Thiophen-2-yl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3z)

22.0 mg, 69% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid, mp = 128-130°C. ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.76 (m, 2H), 7.37 – 7.32 (m, 1H), 7.17 (d, *J* = 8.2 Hz, 2H), 7.15 – 7.13 (m, 1H), 6.96 – 6.93 (m, 1H), 5.95 – 5.89 (m, 1H), 4.63 (d, *J* = 1.5 Hz, 2H), 2.26 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.3, 151.3, 145.2, 135.5, 134.3, 130.3, 129.8, 128.6, 128.2, 128.0, 116.9, 51.9, 21.7. HRMS (ESI-TOF) m/z calcd for C₁₅H₁₃NO₃S₂ (M+H)⁺ 320.0410, found 320.0416.



5-Methyl-4-phenyl-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3aa)

18.0 mg, 55% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid, mp = 152-154°C. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.1 Hz, 2H), 7.48 (q, *J* = 3.6, 2.3 Hz, 5H), 7.36 (d, *J* = 8.1 Hz, 2H), 6.20 (s, 1H), 5.36 – 5.29 (m, 1H), 2.45 (s, 3H), 1.63 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.2, 164.6, 144.9, 136.4, 131.2, 130.5, 129.6, 129.3, 128.1, 127.3, 118.4, 59.8, 21.7, 20.4. HRMS (ESI-TOF) m/z calcd for C₁₈H₁₇NO₃S (M+H)⁺ 328.1002, found 328.1006.

4,5-Diphenyl-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (3ab)

32 mg, 65% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid, mp = 162-164°C. ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.39 (m, 2H), 7.35 – 7.30 (m, 4H), 7.28 (s, 2H), 7.24 – 7.21 (m, 4H), 7.07 (d, *J* = 8.2 Hz, 2H), 6.48 (d, *J* = 1.1 Hz, 1H), 6.26 (d, *J* = 1.2 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 168.2, 161.5, 144.4, 136.1, 134.6, 131.1, 130.2, 129.1, 129.0, 128.9, 128.9, 128.5, 127.7, 127.3, 118.9, 67.0, 21.6. HRMS (ESI-TOF) m/z calcd for C₂₃H₁₉NO₃S (M+H)⁺ 390.1158, found 390.1160.



Tert-butyl 4-(4-chlorophenyl)-2-oxo-2,5-dihydro-1*H***-pyrrole-1-carboxylate (3ac)** 38 mg, 83% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.44 (m, 4H), 6.42 (s, 1H), 4.69 (s, 2H), 1.61 (s, 9H). Compound **3ac** is known compound, and the proton spectrum is fully consistent with literature reported.^{S12}

4-Phenylfuran-2(5H)-one (5a)

22.4 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.53 (t, *J* = 6.3 Hz, 5H), 6.41 (s, 1H), 5.26 (s, 2H). Compound **5a** is known compound, and the proton spectrum is fully consistent with literature reported.^{S9}

4-(4-Methoxyphenyl)furan-2(5H)-one (5b)

27.4 mg, 72% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 7.8 Hz, 2H), 6.99 (d, *J* = 7.8 Hz, 2H), 6.26 (s, 1H), 5.21 (s, 2H), 3.89 (s, 3H).

Compound **5b** is known compound, and the proton spectrum is fully consistent with literature reported.^{S9}



4-(*p*-Tolyl)furan-2(5*H*)-one (5c)

24.4 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (600 MHz, CDCl₃) δ 7.33 (d, *J* = 7.9 Hz, 2H), 7.21 (s, 2H), 6.25 (s, 1H), 5.14 (s, 2H), 2.34 (s, 3H).

Compound 5c is known compound, and the proton spectrum is fully consistent with literature reported.^{S9}



4-(4-Chlorophenyl)furan-2(5H)-one (5d)

26.4 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 4H), 6.40 (t, *J* = 1.9 Hz, 1H), 5.22 (d, *J* = 1.7 Hz, 2H).

Compound **5d** is known compound, and the proton spectrum is fully consistent with literature reported.^{S9}



4-(4-Bromophenyl)furan-2(5H)-one (5e)

32.2 mg, 68% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.60 (m, 2H), 7.46 – 7.34 (m, 2H), 6.41 (t, *J* = 1.8 Hz, 1H), 5.22 (d, *J* = 1.8 Hz, 2H).

Compound **5e** is known compound, and the proton spectrum is fully consistent with literature reported.^{S13}



4-(*m*-Tolyl)furan-2(5*H*)-one (5f)

24.0 mg, 69% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.32 (m, 4H), 6.38 (t, *J* = 1.8 Hz, 1H), 5.24 (d, *J* = 1.8 Hz, 2H), 2.43 (s, 3H).

Compound **5f** is known compound, and the proton spectrum is fully consistent with literature reported.^{S13}



4-(3-Methoxyphenyl)furan-2(5H)-one (5g)

26.6 mg, 70% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41 (t, *J* = 7.8 Hz, 1H), 7.13 – 7.00 (m, 3H), 6.39 (t, *J* = 0.9 Hz, 1H), 5.25 – 5.19 (m, 2H), 3.88 (s, 3H).

Compound 5g is known compound, and the proton spectrum is fully consistent with literature reported.^{S15}



4-(3-Chlorophenyl)furan-2(5H)-one (5h)

27.0 mg, 69% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.53 – 7.38 (m, 4H), 6.43 (t, *J* = 1.9 Hz, 1H), 5.23 (d, *J* = 1.8 Hz, 2H).

Compound **5h** is known compound, and the proton spectrum is fully consistent with literature reported.^{S16}



4-(3-Bromophenyl)furan-2(5H)-one (5i)

55 mg, 67% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.63 (m, 2H), 7.46 (d, *J* = 7.9 Hz, 1H), 7.39 (d, *J* = 8.2 Hz, 1H), 6.46 – 6.37 (m, 1H), 5.22 (d, *J* = 1.8 Hz, 2H).

Compound **5i** is known compound, and the proton spectrum is fully consistent with literature reported.^{S16}



4-(o-Tolyl)furan-2(5H)-one (5j)

21.6 mg, 62% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (600 MHz, CDCl₃) δ 7.32 – 7.29 (m, 1H), 7.27 – 7.19 (m, 3H), 6.20 (t, *J* = 1.8 Hz, 1H), 5.12 (d, *J* = 1.8 Hz, 2H), 2.41 (s, 3H).

Compound **5j** is known compound, and the proton spectrum is fully consistent with literature reported.^{S14}

4-(2-Methoxyphenyl)furan-2(5H)-one (5k)

22.8 mg, 60% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (600 MHz, CDCl₃) δ 7.28 – 7.18 (m, 2H), 6.86 – 6.76 (m, 2H), 6.36 (s, 1H), 5.07 (s, 2H), 3.73 (s, 3H).

Compound 5k is known compound, and the proton spectrum is fully consistent with literature reported.^{S14}



4-(2-Fluorophenyl)furan-2(5H)-one (5l)

21.0 mg, 57% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. mp = 145-147°C. ¹H NMR (400 MHz, CDCl₃) δ 7.57 – 7.45 (m, 2H), 7.32 – 7.19 (m, 2H), 6.55 (q, *J* = 1.7 Hz, 1H), 5.29 (t, *J* = 1.7 Hz, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 173.7, 161.0 (d, *J* = 255.6 Hz), 158.4, 133.4 (d, *J* = 8.9 Hz), 128.2 (d, *J* = 3.1 Hz), 125.0 (d, *J* = 3.3 Hz), 117.0, 116.9, 116.3 (d, *J* = 8.6 Hz), 72.0 (d, *J* = 8.5 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -109.6. HRMS (ESI-TOF) m/z calcd for C₁₀H₇FO₂ (M+H)⁺ 179.0503, found 179.0506.



4-(2-Chlorophenyl)furan-2(5H)-one (5m)

22.5 mg, 58% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (600 MHz, CDCl₃) δ 7.54 – 7.45 (m, 2H), 7.28 – 7.26 (m, 1H), 7.23 – 7.18 (m, 1H), 6.53 (q, *J* = 1.6 Hz, 1H), 5.27 (t, *J* = 1.8 Hz, 2H).

Compound **5m** is known compound, and the proton spectrum is fully consistent with literature reported.^{S14}



4-([1,1'-Biphenyl]-4-yl)furan-2(5*H*)-one (5n)

34.9 mg, 74% yield (silica gel; petroleum ether/ethyl acetate 2:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.4 Hz, 2H), 7.67 – 7.59 (m, 4H), 7.51 (t, J = 7.5 Hz, 2H), 7.46 – 7.43 (m, 1H), 6.47 – 6.40 (m, 1H), 5.29 (d, J = 1.7 Hz, 2H).

Compound **5n** is known compound, and the proton spectrum is fully consistent with literature reported.^{S17}



4-(Naphthalen-2-yl)furan-2(5H)-one (5o)

29.8 mg, 71% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.87 (m, 4H), 7.70 – 7.57 (m, 3H), 6.51 (t, *J* = 1.8 Hz, 1H), 5.38 (d, *J* = 1.8 Hz, 2H).

Compound **50** is known compound, and the proton spectrum is fully consistent with literature reported.^{S13}



4-(Thiophen-2-yl)furan-2(5H)-one (5p)

22.9 mg, 69% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.57 (m, 1H), 7.37 – 7.31 (m, 1H), 7.21 – 7.14 (m, 1H), 6.20 (t, *J* = 1.7 Hz, 1H), 5.19 (d, *J* = 1.7 Hz, 2H).

Compound **5p** is known compound, and the proton spectrum is fully consistent with literature reported.^{S18}



4-(4-Chlorophenyl)-1,5-dihydro-2*H*-pyrrol-2-one (6)

16.4 mg, 85% yield from **30**; 18.7 mg, 97% yield from **3ac** (silica gel; petroleum ether/ethyl acetate 2:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.41 (m, 4H), 6.52 (s, 1H), 6.44 (s, 1H), 4.42 (s, 2H).

Compound 6 is known compound, and the proton spectrum is fully consistent with literature reported.^{S12}

N-((1-Benzyl-5-(2-phenylaziridin-1-yl)-1*H*-1,2,3-triazol-4-yl)(phenyl)methyl)-*N*-ethylaniline (9)

22.6 mg, 91% yield (silica gel; petroleum ether/ethyl acetate 3:1), brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.87 – 7.80 (m, 2H), 7.59 – 7.50 (m, 5H), 7.46 – 7.40 (m, 2H), 7.39 – 7.33 (m, 1H), 6.24 (s, 1H), 6.21 (s, 1H).

Compound **9** is known compound, and the proton spectrum is fully consistent with literature reported.^{S19}

13.References

(S1) Xu, Y.; Hu, X. Org. Lett. 2019, 21, 8091-8096.

(S2) Sontakke, G. S.; Pal, K.; Volla, C. M. R. Org. Lett. 2022, 24, 8796-8801.

(S3) Gómez, J. E.; Cristòfol, À.; Kleij, A. W. Angew. Chem. Int. Ed. 2019, 58, 3903-3907.

(S4) Lang, Q.; Gu, G.; Cheng, Y.; Yin, Q; Zhang, X. Highly enantioselective synthesis of chiral *γ*-lactams by Rh-catalyzed asymmetric hydrogenation. *Acs Catal.*, **2018**, *8*, 4824-4828.

(S5) Kancharla, P.; Kelly, J. X.; Reynolds, K. A. Synthesis and structure-activity relationships of tambjamines and B-Ring functionalized prodiginines as potent antimalarials. *J. Med. Chem.*, **2015**, *58*, 7286-7309.

(S6) Miao S.; Andersen, R. J. Rubrolides A-H, metabolites of the colonial tunicate Ritterella rubra. *J. Org. Chem.*, **1991**, *56*, 6275-6280.

(S7) Varejão, J. O. S.; Barbosa, L. C. A.; Varejão, E. V. V.; Coreas, N. M. G.; Morais, V. S. S.; de Oliveira, A. M.; Barcelos, R. C.; Maltha, C. R. Á.; Modolo, L. V. Rubrolide analogues as urease inhibitors. *Monatsh. Chem.*, **2023**, *154*, 1177-1187.

(S8) Zhou, Y.; Guo, S. Huang, Q.; Lang, Q.; Chen, G.; Zhang, X. Facile access to chiral γ -butyrolactones via rhodium-catalysed asymmetric hydrogenation of γ -butenolides and γ -hydroxybutenolides. *Chem. Sci.*, **2023**, *14*, 4888-4892.

(S9) Kiran, K. Y.; Ranjith, K. G.; Sridhar, R. M. Org. Biomol. Chem. 2016, 14, 1252-60.

(S10) Huizar, F. J.; Hill, H. M.; Bacher, E. P.; Eckert, K. E.; Gulotty, E. M.; Rodriguez, K. X.; Tucker, Z. D.; Banerjee, M.; Liu, H. N.; Wiest, O.; Zartman, J.; Ashfeld, B. L. *ChemMedChem* **2022**, *17*.

(S11) Vorona, M.; Orlova, N.; Kuznetsov, E.; Vikainis, S.; Liepinsh, E.; Belyakov, S.; Mishnev, A.; Veinberg, G. *Chem. Heterocycl. Com.*+ **2013**, *49*, 1118-1127.

(S12) Lang, Q.; Gu, G.; Cheng, Y.; Yin, Q.; Zhang, X. ACS Catal. 2018, 8, 4824-4828.

(S13) Kiyokawa, K.; Takemoto, K.; Yahata, S.; Kojima, T.; Minakata, S. *Synthesis-Stuttgart* **2017**, *49*, 2907-2912.

(S14) Cacchi, S.; Fabrizi, G.; Goggiamani, A.; Sferrazza, A. Synlett 2009, 1277-1280.

(S15) Taniguchi, T.; Nagata, H.; Kanada, R. M.; Kadota, K.; Takeuchi, M.; Ogasawara, K. *Heterocycles* **2000**, *52*, 67-71.

(S16) Karak, M.; Barbosa, L. C. A.; Maltha, C. R. A.; Silva, T. M.; Boukouvalas, J. *Tetrahedron Lett.* **2017**, *58*, 2830-2834.

(S17) Gronnier, C.; Kramer, S.; Odabachian, Y.; Gagosz, F. J. Am. Chem. Soc. 2012, 134, 828-831.

(S18) Wu, J.; Zhu, Q.; Wang, L.; Fathi, R.; Yang, Z. J. Org. Chem. 2003, 68, 670-673.

(S19) Sontakke, G. S.; Pal, K.; Volla, C. M. R. Org. Lett. 2022, 24, 8796-8801.

14.NMR spectra



Figure S2. ¹H NMR spectrum of **3a** in CDCl₃ (400 MHz) at 23°C.



Figure S3. ¹H NMR spectrum of **3b** in CDCl₃ (400 MHz) at 23°C.



Figure S4. ¹³C NMR spectrum of 3**b** in CDCl₃ (150 MHz) at 23°C.



Figure S5. ¹H NMR spectrum of 3**c** in CDCl₃ (400 MHz) at 23°C.





Figure S7. ¹H NMR spectrum of **3d** in CDCl₃ (400 MHz) at 23°C.



Figure S8. ¹³C NMR spectrum of 3d in CDCl₃ (150 MHz) at 23°C.



Figure S9. ¹H NMR spectrum of **3e** in CDCl₃ (400 MHz) at 23°C.



Figure S10. ¹³C NMR spectrum of **3e** in CDCl₃ (150 MHz) at 23°C.



Figure S11. ¹H NMR spectrum of **3f** in CDCl₃ (600 MHz) at 23°C.


Figure S12. ¹H NMR spectrum of 3**g** in CDCl₃ (400 MHz) at 23°C.



Figure S13. ¹³C NMR spectrum of 3g in $CDCl_3$ (100 MHz) at 23°C.



Figure S14. ¹H NMR spectrum of **3h** in CDCl₃ (400 MHz) at 23°C.



Figure S15. ¹³C NMR spectrum of **3h** in CDCl₃ (150 MHz) at 23°C.



Figure S16. ¹H NMR spectrum of **3i** in CDCl₃ (400 MHz) at 23°C.



Figure S17. ¹³C NMR spectrum of 3i in CDCl₃ (100 MHz) at 23°C.



Figure S18. ¹H NMR spectrum of **3j** in CDCl₃ (600 MHz) at 23°C.



Figure S19. ¹³C NMR spectrum of 3j in CDCl₃ (150 MHz) at 23°C.



Figure S20. ¹H NMR spectrum of **3k** in CDCl₃ (400 MHz) at 23°C.





Figure S22. ¹H NMR spectrum of **3m** in CDCl₃ (400 MHz) at 23°C.





Figure S24. ¹H NMR spectrum of **3n** in CDCl₃ (400 MHz) at 23°C.





Figure S26. ¹H NMR spectrum of **30** in CDCl₃ (400 MHz) at 23°C.





Figure S28. ¹H NMR spectrum of **3p** in CDCl₃ (400 MHz) at 23°C.





Figure S30. ¹H NMR spectrum of **3q** in CDCl₃ (400 MHz) at 23°C.





Figure S32. ¹H NMR spectrum of **3r** in CDCl₃ (400 MHz) at 23°C.





Figure S34. ¹H NMR spectrum of 3s in CDCl₃ (400 MHz) at 23°C.



Figure S35. ¹³C NMR spectrum of **3s** in CDCl₃ (150 MHz) at 23°C.



Figure S36. ¹H NMR spectrum of 3t in CDCl₃ (400 MHz) at 23°C.



Figure S37. ¹³C NMR spectrum of **3t** in CDCl₃ (100 MHz) at 23°C.



Figure S38. ¹H NMR spectrum of **3u** in CDCl₃ (400 MHz) at 23°C.



Figure S39. ¹³C NMR spectrum of **3u** in CDCl₃ (150 MHz) at 23°C.



Figure S40. ¹H NMR spectrum of **3v** in CDCl₃ (400 MHz) at 23°C.



Figure S41. ¹³C NMR spectrum of 3v in CDCl₃ (100 MHz) at 23°C.



Figure S42. ¹H NMR spectrum of **3w** in CDCl₃ (400 MHz) at 23°C.





S69





Figure S46. ¹H NMR spectrum of **3x** in CDCl₃ (600 MHz) at 23°C.



Figure S47. ¹³C NMR spectrum of 3x in CDCl₃ (150 MHz) at 23°C.


Figure S48. ¹H NMR spectrum of **3y** in CDCl₃ (600 MHz) at 23°C.





Figure S50. ¹H NMR spectrum of **3z** in CDCl₃ (400 MHz) at 23°C.



Figure S51. ¹³C NMR spectrum of 3z in CDCl₃ (150 MHz) at 23°C.



Figure S52. ¹H NMR spectrum of **3aa** in CDCl₃ (400 MHz) at 23°C.



Figure S53. ¹³C NMR spectrum of 3aa in CDCl₃ (150 MHz) at 23°C.



Figure S54. ¹H NMR spectrum of **3ab** in CDCl₃ (400 MHz) at 23°C.



Figure S55. ¹³C NMR spectrum of **3ab** in CDCl₃ (150 MHz) at 23°C.



Figure S56. ¹H NMR spectrum of **3ac** in CDCl₃ (400 MHz) at 23°C.



Figure S57. ¹H NMR spectrum of **5a** in CDCl₃ (400 MHz) at 23°C.



Figure S58. ¹H NMR spectrum of **5b** in CDCl₃ (400 MHz) at 23°C.



Figure S59. ¹H NMR spectrum of **5c** in CDCl₃ (600 MHz) at 23°C.



Figure S60. ¹H NMR spectrum of **5d** in CDCl₃ (400 MHz) at 23°C.



Figure S61. ¹H NMR spectrum of **5e** in CDCl₃ (400 MHz) at 23°C.



Figure S62. ¹H NMR spectrum of 5f in CDCl₃ (400 MHz) at 23°C.



Figure S63. ¹H NMR spectrum of **5g** in CDCl₃ (400 MHz) at 23°C.



Figure S64. ¹H NMR spectrum of **5h** in CDCl₃ (400 MHz) at 23°C.



Figure S65. ¹H NMR spectrum of 5i in CDCl₃ (400 MHz) at 23°C.



Figure S66. ¹H NMR spectrum of **5j** in CDCl₃ (600 MHz) at 23°C.



Figure S67. ¹H NMR spectrum of 5k in CDCl₃ (600 MHz) at 23°C.



Figure S68. ¹H NMR spectrum of 5l in CDCl₃ (400 MHz) at 23°C.



Figure S69. ¹³C NMR spectrum of **5**l in CDCl₃ (150 MHz) at 23°C.



Figure S70. Local magnification ¹³C NMR spectrum of **3w** in CDCl₃ (150 MHz) at 23°C.





Figure S72. ¹H NMR spectrum of **5m** in CDCl₃ (600 MHz) at 23°C.



Figure S73. ¹H NMR spectrum of **5n** in CDCl₃ (400 MHz) at 23°C.



Figure S74. ¹H NMR spectrum of **50** in CDCl₃ (400 MHz) at 23°C.



Figure S75. ¹H NMR spectrum of **5P** in CDCl₃ (400 MHz) at 23°C.



Figure S76. ¹H NMR spectrum of **6** in CDCl₃ (400 MHz) at 23°C.



Figure S77. ¹H NMR spectrum of **9** in CDCl₃ (400 MHz) at 23°C.